Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL

Clinical trial NCT06890585 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06890585
Sponsor: Li Zhiming
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

BTK Inhibitors Histone Deacetylase Inhibitor Double Express Diffuse Large B-cell Lymphoma

Start date: 2025-06-01
Primary completion: 2029-12-31
Enrollment: 128

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.